362 related articles for article (PubMed ID: 14579513)
1. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
2. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
3. Ion channels in T cells: from molecular pharmacology to therapy.
Krasznai Z
Arch Immunol Ther Exp (Warsz); 2005; 53(2):127-35. PubMed ID: 15928581
[TBL] [Abstract][Full Text] [Related]
4. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
5. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Vennekamp J; Wulff H; Beeton C; Calabresi PA; Grissmer S; Hänsel W; Chandy KG
Mol Pharmacol; 2004 Jun; 65(6):1364-74. PubMed ID: 15155830
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in healthy pregnancy and preeclampsia.
Toldi G; Stenczer B; Treszl A; Kollár S; Molvarec A; Tulassay T; Rigó J; Vásárhelyi B
Am J Reprod Immunol; 2011 Feb; 65(2):154-63. PubMed ID: 20649894
[TBL] [Abstract][Full Text] [Related]
7. Potassium channel expression in human CD4+ regulatory and naïve T cells from healthy subjects and multiple sclerosis patients.
Varga Z; Csepany T; Papp F; Fabian A; Gogolak P; Toth A; Panyi G
Immunol Lett; 2009 Jun; 124(2):95-101. PubMed ID: 19409928
[TBL] [Abstract][Full Text] [Related]
8. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
Felix JP; Bugianesi RM; Schmalhofer WA; Borris R; Goetz MA; Hensens OD; Bao JM; Kayser F; Parsons WH; Rupprecht K; Garcia ML; Kaczorowski GJ; Slaughter RS
Biochemistry; 1999 Apr; 38(16):4922-30. PubMed ID: 10213593
[TBL] [Abstract][Full Text] [Related]
9. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.
Orbán C; Bajnok A; Vásárhelyi B; Tulassay T; Toldi G
Cytometry A; 2014 Jul; 85(7):636-41. PubMed ID: 24827427
[TBL] [Abstract][Full Text] [Related]
10. Ion channels and lymphocyte activation.
Panyi G; Varga Z; Gáspár R
Immunol Lett; 2004 Mar; 92(1-2):55-66. PubMed ID: 15081528
[TBL] [Abstract][Full Text] [Related]
11. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
[TBL] [Abstract][Full Text] [Related]
12. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
[TBL] [Abstract][Full Text] [Related]
13. Targeting effector memory T-cells with Kv1.3 blockers.
Wulff H; Pennington M
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
[TBL] [Abstract][Full Text] [Related]
14. K+ channels and T-cell synapses: the molecular background for efficient immunomodulation is shaping up.
Matkó J
Trends Pharmacol Sci; 2003 Aug; 24(8):385-9. PubMed ID: 12915045
[TBL] [Abstract][Full Text] [Related]
15. Potassium channels, memory T cells, and multiple sclerosis.
Beeton C; Chandy KG
Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596
[TBL] [Abstract][Full Text] [Related]
16. The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression.
Jensen BS; Hertz M; Christophersen P; Madsen LS
Expert Opin Ther Targets; 2002 Dec; 6(6):623-36. PubMed ID: 12472376
[TBL] [Abstract][Full Text] [Related]
17. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
Koo GC; Blake JT; Shah K; Staruch MJ; Dumont F; Wunderler D; Sanchez M; McManus OB; Sirotina-Meisher A; Fischer P; Boltz RC; Goetz MA; Baker R; Bao J; Kayser F; Rupprecht KM; Parsons WH; Tong XC; Ita IE; Pivnichny J; Vincent S; Cunningham P; Hora D; Feeney W; Kaczorowski G
Cell Immunol; 1999 Nov; 197(2):99-107. PubMed ID: 10607427
[TBL] [Abstract][Full Text] [Related]
18. Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.
Valverde P; Kawai T; Taubman MA
J Dent Res; 2005 Jun; 84(6):488-99. PubMed ID: 15914584
[TBL] [Abstract][Full Text] [Related]
19. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
20. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
Toldi G; Bajnok A; Dobi D; Kaposi A; Kovács L; Vásárhelyi B; Balog A
Immunobiology; 2013 Mar; 218(3):311-6. PubMed ID: 22705192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]